These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22409299)

  • 21. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
    Weiss GJ; Infante JR; Chiorean EG; Borad MJ; Bendell JC; Molina JR; Tibes R; Ramanathan RK; Lewandowski K; Jones SF; Lacouture ME; Langmuir VK; Lee H; Kroll S; Burris HA
    Clin Cancer Res; 2011 May; 17(9):2997-3004. PubMed ID: 21415214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Let kids be kids.
    Lancet Oncol; 2004 Nov; 5(11):641. PubMed ID: 15522649
    [No Abstract]   [Full Text] [Related]  

  • 23. Anticancer drugs.
    Reese DM
    Nature; 1995 Dec; 378(6557):532. PubMed ID: 8524372
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski's Rule of Five.
    Chagas CM; Moss S; Alisaraie L
    Int J Pharm; 2018 Oct; 549(1-2):133-149. PubMed ID: 30040971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What affects patient adherence to oral chemotherapy?
    Bosley C
    ONS Connect; 2012 Apr; 27(4):24. PubMed ID: 22662589
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia.
    Miedema KG; de Bont ES; Oude Nijhuis CS; van Vliet D; Kamps WA; Tissing WJ
    J Clin Oncol; 2011 Mar; 29(7):e182-4; author reply e185. PubMed ID: 21245423
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 31. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.
    Burtness B; Belker M; Stoltz M; Peccerillo KM; Lamb LA; Chmael SE; McKeon A; Clark MB; Winship J; Marsh JC; Pizzorno G; DeVita VT
    Cancer J; 2000; 6(5):309-15. PubMed ID: 11079170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redefining dose-limiting toxicity.
    Postel-Vinay S
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):87-9. PubMed ID: 25774476
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
    Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
    J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative dose intensity: improving cancer treatment and outcomes.
    Lenhart C
    Oncol Nurs Forum; 2005 Jul; 32(4):757-64. PubMed ID: 15990905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
    J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
    Baldo P
    Recent Pat Anticancer Drug Discov; 2019; 14(3):202. PubMed ID: 31778105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.